AEMD Stock Forecast: Aethlon Medical, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Aethlon Medical, Inc. is $13. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Aethlon Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (8): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AEMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AEMD, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | $1.50 |
| 7 July 2025 | HC Wainwright & Co. | Assumes | Neutral | $1.50 |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2022 | Maxim Group | Downgrade | Hold | — |
| 25 June 2021 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $9.00 |
| 1 June 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Jan 2021 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AEMD.
This page is one stock. Monday covers all of them.
AEMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AEMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 55% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −136.8%
- Return on assets
- −70.3%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aethlon Medical, Inc. has a market value of $8.8M and an enterprise value of $2.5M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$7.2M.
Free cash flow in the twelve months to 31 Mar 2026: −$7.0M.
Aethlon Medical, Inc. employs 9 people.
Data provided by Twelve Data
AEMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AEMD’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Aethlon Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AEMD
What is the AEMD stock price forecast for 2026-2027?
The median 12-month analyst price target for Aethlon Medical, Inc. is $13, with estimates ranging from $1.5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AEMD stock a buy right now?
Of the 2 analysts covering Aethlon Medical, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aethlon Medical, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AEMD?
As at 21 Nov 2026, Aethlon Medical, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).
Will AEMD stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $13, and Ticker Nerd's factor model ranks Aethlon Medical, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AEMD stock forecast for 2030?
No analyst covering Aethlon Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $25 over the next 12 months.
What does Aethlon Medical, Inc. do?
Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease. Its lead product, the Hemopurifier, is a clinical-stage extracorporeal device designed to remove circulating disease-related targets from blood and other biologic fluids.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease. Its lead product, the Hemopurifier, is a clinical-stage extracorporeal device designed to remove circulating disease-related targets from blood and other biologic fluids. The company’s work spans applications in cancer care, life-threatening viral infections, and organ transplantation, with a broader emphasis on addressing unmet needs in medical treatment and biodefense. Aethlon Medical combines device-based therapy and filtration science to support clinical research in areas where current options remain limited. Headquartered in San Diego, California, the company operates as a specialized player in the healthcare sector, concentrating on advanced therapeutic devices rather than broad pharmaceutical products.
CEO Mr. James B. Frakes M.B.A. · 9 employees · United States · https://www.aethlonmedical.com